A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Inclusion Criteria: * Subjects aged from 18 to 75 years (including the boundary value) * At the time of screening, the diagnosis of atopic dermatitis (AD) meets the Hanifin-Rajka criteria, with a disease history of ≥1 year prior to screening. * During the screening period and prior to randomization: EASI score ≥16, IGA score ≥3, BSA ≥10%. Exclusion Criteria: * People who have previously used or participated in clinical trials of monoclonal antibody with the same target or dupilumab * Having participated in drug or device clinical trials within 12 weeks or 5 half-lives of other investigational drugs before the study administration. * Subjects who have received live vaccines or live-attenuated vaccines within 12 weeks prior to randomization or plan to receive such vaccines during the trial period.